Navigation Links
EMD Serono and FAST FORWARD, LLC Announce Collaboration to Accelerate Development of Treatments for Multiple Sclerosis
Date:3/18/2009

-- EMD Serono and Fast Forward agree to work together to speed research development on a select group of high potential MS research projects with support of up to $19 million in funding

ROCKLAND, Mass. and NEW YORK, March 18/PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt Germany, and Fast Forward, LLC, a wholly-owned subsidiary of the National Multiple Sclerosis Society, today announced a collaborative partnership to evaluate and fund promising multiple sclerosis (MS) research projects. Proposals will be jointly developed by EMD Serono and Fast Forward. Merck KGaA, the parent corporation of EMD Serono, Inc., will provide up to $19 million in funding. The funds will support early stage clinical development projects with biotech companies or projects with individual researchers or academic institutions.

To speed MS research and clinical development, the companies have entered into a two-year worldwide agreement that may extend for an additional three years.

"EMD Serono and the National MS Society have an unwavering commitment to the support of early stage research in the quest to find new and improved treatment options for MS patients. It is with great excitement that our organization supports this initiative with Fast Forward, which will explore new avenues to advance new MS treatments with the potential to transform people's lives," said Fereydoun Firouz, President and CEO, EMD Serono Inc.

Fast Forward, LLC was established by the National Multiple Sclerosis Society to help bridge the gap between research and drug development. To accomplish this goal, Fast Forward partners with early stage biotechnology and pharmaceutical companies to advance therapies, diagnostics, medical devices, and related technologies to treat, reverse, and ultimately cure MS. Fast Forward is committed to deploying its resources to spur development of innovative MS therapies and bring them to market as quickly as possible.

"Thanks to the National Multiple Sclerosis Society's history of supporting MS research and program services for people with MS, we have tremendous knowledge about multiple sclerosis and the needs of people with MS. Yet the ability of research institutions and business to bring projects forward is lagging, particularly in this uncertain economic climate," said Dr. Tim Coetzee, Fast Forward's Executive Director. "Partnerships with industry leaders like Merck KGaA and EMD Serono equip us to move even more aggressively toward our shared goal of a world free of MS."

"Identification of innovative opportunities to change the MS treatment paradigm is a critical aspect of addressing this disease. We are pleased to bring to this alliance not only its financial support, but our years of expertise and commitment in the field of MS research and development," said Bernhard Kirschbaum, PhD, Executive Vice President, Global Research and Development, Merck Serono.

The Early Stage Commercial Company Fund and the Innovation Accelerator Fund, the two programs in the EMD Serono collaboration, complement Fast Forward's ongoing efforts to spur early-stage drug discovery for MS. Both programs will provide critical resources to underfunded stages of the drug development process and align with Fast Forward's strategy to identify the most promising drug discovery research and accelerate the drug development process by providing financial resources to move it forward.

Fast Forward will disseminate requests for proposals (RFPs) in Q2 2009 with initial funding of proposals anticipated by December 2009. The overall selection of program awardees will be made exclusively by Fast Forward, with participation by EMD Serono Inc. under Fast Forward's standard assessment process. The priority areas to be selected for development partnership will be determined by a joint committee comprising Fast Forward staff and representatives from EMD Serono and Merck KGaA. All funding disbursements will be managed and approved by the Fast Forward Board of Directors.

About multiple sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that more than 2 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

About Fast Forward, LLC

Fast Forward, LLC is a nonprofit organization established by the National Multiple Sclerosis Society in order to accelerate the development of treatments for MS. Fast Forward will accomplish its mission by connecting university-based MS research with private-sector drug development and by funding small biotechnology/pharmaceutical companies to develop innovative new MS therapies and repurpose FDA-approved drugs as new treatments for MS. For more information visit www.fastforward.org

About the National Multiple Sclerosis Society

The National MS Society addresses the challenges of each person affected by MS through funding cutting-edge research, driving change through advocacy, facilitating professional education, collaborating with MS organizations around the world, and providing programs and services designed to help people with MS and their families move their lives forward. In 2008 alone, through the national office and its 500-state network of chapters, the Society devoted over $136 million to programs that enhanced more than one million lives. The Society also invested nearly $50 million to support 440 research projects around the world. The Society is dedicated to achieving a world free of MS. Join the movement at www.nationalMSsociety.org.

About EMD Serono

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, with Rebif(R) (interferon beta-1a), as well as in endocrinology, with Saizen(R) (somatropin (rDNA origin) for injection), Serostim(R) (somatropin (rDNA origin) for injection) and Zorbtive(TM) (somatropin (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alpha for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono's US footprint continues to grow, with more than 1000 employees around the country and fully integrated commercial, clinical and research operations in the company's home state of Massachusetts.

For more information, please visit www.emdserono.com

About Merck KGaA

Merck is a global pharmaceutical and chemical company with total revenues of EUR 7.6 billion in 2008, a history that began in 1668, and a future shaped by 32,800 employees in 59 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit www.merckserono.com or www.merck.de


'/>"/>
SOURCE EMD Serono, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
2. EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. In Recognition of WORLD AIDS DAY, Charlotte Bobcats Power Forward, Emeka Okafor, Launches Mobile Texting Campaign in Support of the One Million African Lives Initiative
5. Presto Announces Donation Program to Help Find the Cure for Multiple Sclerosis
6. Relsys International Announces the Release of the Argus Safety(TM) Suite 5.0
7. Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
8. DiagnoCure announces first quarter 2009 results
9. Carestream Health Announces New Orders From from U.S. Healthcare Facilities For for Its Digital Radiography Solutions
10. InstaMed Announces Osage Partners and Ashby Point Capital Have Joined Existing Investors in $6 Million Growth Equity Financing
11. Board of Certified Hazard Control Management (BCHCM) Announces the Certified Healthcare Emergency Professional (CHEP) Credential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: